IgA glomerulonephritis
Drug research and approvals for igA glomerulonephritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 69 studies of igA glomerulonephritis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 69
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07902817 · Phase 3 · Jade Biosciences, Inc. · starts Dec 1, 2026
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab…NCT07890909 · Phase 3 · Vertex Pharmaceuticals Incorporated · starts Nov 13, 2026
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNCT07850752 · Phase 3 · Novartis Pharmaceuticals · starts Nov 11, 2026
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic…NCT07822100 · Not applicable · Hong Zhang · starts Aug 24, 2026
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANNCT07773727 · Phase 2 · argenx · starts Nov 5, 2026
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyNCT07616700 · Phase 2 · Haisco Pharmaceutical Group Co., Ltd. · starts Aug 25, 2025
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected…NCT07614477 · Phase 2 · Everest Medicines (China) Co.,Ltd. · starts May 20, 2026
- Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) NephropathyNCT07606352 · Phase 2 · Sitala Bio LTD · starts Aug 4, 2026
Approved 3
- IptacopanComplement factor B inhibitor
- SparsentanEndothelin receptor ET-A antagonist
- BudesonideGlucocorticoid receptor agonist
Phase 3 12 of 18
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Telitacicept
- Zigakibart
- AzathioprineAmidophosphoribosyltransferase inhibitor
- IrbesartanType-1 angiotensin II receptor antagonist
- LosartanType-1 angiotensin II receptor antagonist
- CyclophosphamideDNA inhibitor
- AtrasentanEndothelin receptor ET-A antagonist
- AtaciceptTumor necrosis factor ligand superfamily member 13B inhibitor
- BlisibimodTumor necrosis factor ligand superfamily member 13B inhibitor
- AliskirenRenin inhibitor
Phase 2 12 of 18
- SibeprenlimabTumor necrosis factor ligand superfamily member 13 inhibitor
- EnalaprilAngiotensin-converting enzyme inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- AtorvastatinHMG-CoA reductase inhibitor
- Omega-3-ACID ethyl esters
- AvacopanC5a anaphylatoxin chemotactic receptor antagonist
- FostamatinibTyrosine-protein kinase SYK inhibitor
- CemdisiranComplement C5 mRNA RNAi inhibitor
- FelzartamabLymphocyte differentiation antigen CD38 inhibitor
- TegoprubartCD40 ligand inhibitor
How its trials ended
184 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 41 whose ending is known, 41% met their primary endpoint, 7% missed it and 51% stopped early.
- Ongoing6636%
- Completed, result not reported4927%
- Status unknown2815%
- Met its primary endpoint179%
- Stopped: other or unclear84%
- Stopped: sponsor or business decision74%
- Stopped: enrollment or feasibility42%
- Missed its primary endpoint32%
- Stopped: lack of efficacy21%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA